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INTRODUCTION 
 
 
Coronavirus disease 2019 (COVID-19) outbreak caused 
by the novel corona virus was declared as a Public 
Health Emergency of International Concern on 30 
January 2020 and recognized as a pandemic by the 
World Health Organization on March 11, 2020. As per 
the coronavirus disease 2019 (COVID-19) Situation 
Report –88 by WHO dated April 17, 2020, the number 
of reported confirmed cases exceeded 2 million 
globally.1 Subjects infected with COVID-19 often 
present with dry cough, fever, and fatigue at onset, 
myalgia, sore throat, nasal congestion, runny nose, 
headache and diarrhoea in mild to moderate cases and 
may have a rapid progression to acute respiratory 
distress syndrome, septic shock, uncorrectable 
metabolic acidosis, coagulopathy, and multiple organ 
failure in severe cases.2,3 No available drug or vaccine is 
specifically approved for this virus in clinical practice, 
so it is an important task to find and develop such drugs 
that can inhibit SARS-CoV-2 infection. However, before 
a drug or vaccine is available in the market, it must go 
through multiple phases of drug development 
including safety and efficacy trials and this cycle is a 
time intensive procedure, so the selection of drugs with 
anti-SARS-CoV-2 activity among existing clinically 
available drugs has become a faster option at present. 
Till now, many clinical trials involving new coronavirus 
therapy have been registered nationwide, mainly 
involving antimalarials and antiviral drugs. 
 
Hydroxychloroquine was synthesized in 1946 and 
marketed in 1955 as a safe alternative to chloroquine.4   
 
 
It is currently mainly used for rheumatoid arthritis, 
juvenile chronic arthritis, mild systemic and discoid 
lupus erythematosus and the suppression and 
treatment of malaria, and photosensitivity disorders. 
The pharmacokinetics and clinical adverse effects of 
hydroxychloroquine have been established; however, 
since the target population of new indications, dosage 
and time are different from the previous application, 
there is a risk of adverse reactions and even serious 
adverse consequences. Therefore, it is necessary to 
comprehensively review the pharmacological effects, 
metabolism, and distribution in vivo, poisoning and 
toxicological mechanism of chloroquine drugs, 
enhance the understanding of medical workers, 
forensic doctors and the public on acute toxicity of this 
drug, timely detect and reasonably treat serious adverse 
reactions, reduce adverse reactions as well as even 
death caused by drug use. 
 
Many trials assessing the efficacy of 
hydroxychloroquine against COVID-19 have been 
registered worldwide. Chen Z et al conducted a placebo 
controlled randomized trial with two different doses of 
hydroxychloroquine in 62 subjects who reported small 
improvements in body temperature and cough in the 
treatment group taking the higher dose.5 
 
Off-label use of a drug refers to a situation where it is 
prescribed for an indication, route of administration or 
patient group not included in the labelling document of 
the drug. Till now, no medication has been approved by  
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Therapeutic Goods Administration for COVID-19.6 
 
Due to weak evidence of clinical benefits of 
hydroxychloroquine against COVID-19 and poor clarity 
on antiviral mechanism of action of this drug, the drug 
manufacturers have not included this disease as an 
indication in the product document. It is proposed that 
hydroxychloroquine could inhibit viral entry into host 
cells and interferes with the acidification of host cell 
lysosomes. Yao X et al.7 and Liu Y et al.8 conducted in-
vitro studies and reported that hydroxychloroquine can 
inhibit the replication of SARS-CoV-2.  
 
Although, long term use of hydroxychloroquine can 
result in serious cutaneous adverse reactions, fulminant 
hepatic failure, maculopathies, macular degeneration, 
retinopathy, torsade de pointes, ventricular 
tachycardia, cardiomyopathy and cardiac failure but it 
has been permitted by the USFDA and also advocated 
by the Indian Council for Medical Research because no 
definite treatment for COVID-19 is available yet.9,10 
Since the start of this novel coronavirus outbreak, 
hydroxychloroquine has been applied in clinical 
practice and is expected to play an important role in 
controlling the pandemic. Researchers are involved in 
conducting trials of hydroxychloroquine but there is 
scarcity of evidence to support its efficacy in preventing 
COVID-19. Prophylaxis with hydroxychloroquine 
against COVID-19 needs to be thoroughly evaluated in 
observational studies and high quality randomized 
controlled trials. It is also necessary to strengthen the 
understanding of this drug and their toxicological 
characteristics. 
 
CONCLUSION 
There has been an urgent worldwide demand for 
treatments as a result of the essentially untreatable 
coronavirus disease, but no intervention can be 
assumed to be efficacious. The use of 
hydroxychloroquine is being trialled to investigate its 
capability in inhibiting coronavirus. However, it is also 
important to consider the toxicological profile before 
rational use of hydroxychloroquine. A breakthrough in 
the effective treatment with vaccine or drug for 
coronavirus infection may take time, but prevention 
with empiric drugs that target specific structures in the 
virus along with supportive measures can be of great 
help and relief. Along with efficacy studies, it is also 
important to check the safety profile of drugs like 
hydroxychloroquine. There is a need of conducting in-
vitro studies as well as in-vivo randomized controlled 
trials of hydroxychloroquine to find out how effective it 
can be in preventing and treating coronavirus 
infections at doses which do not cause any potential 
adverse reactions in humans. 
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